Login / Signup

Resmetirom: The First Food and Drug Administration-Approved Medication for Nonalcoholic Steatohepatitis (NASH).

Erenie H GuirguisJohn A DoughertyKrisy-Ann ThornbyYasmin GraceKeri Mack
Published in: The Annals of pharmacotherapy (2024)
Resmetirom serves as an attractive option in patients diagnosed with NASH with evidence of advanced fibrosis (F2-F3) in combination with exercise, diet, and other multimodal therapies targeting metabolic risk factors.
Keyphrases